Managing Patients with Rheumatoid Arthritis After TNF Inhibitor or Methotrexate Failure

The Rheumatoid Arthritis Vital Education Initiative: New Horizons in Therapeutic Options (RAVE New Horizons)
1 AMA PRA Category 1 Credit(s)
Launch Date:
August 14, 2018
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

This activity is intended for rheumatologists; PAs; NPs and nurses in rheumatology practices; and some internal medicine clinicians.

Relevant Terms:

rheumatology, rheumatoid arthritis

Jonathan Samuels, MD

Jonathan Samuels, MD
Associate Professor of Medicine
Division of Rheumatology
NYU Langone Health

New York, NY

Dr. Samuels is an Associate Professor in the Department of Medicine (Rheumatology), working with rheumatoid arthritis (RA) patients in many capacities over the last 8 years.  He spent a few years, during a fellowship at Cornell, focusing on a translational research study about B cell tolerance in RA, and enrolling clinic patients.  The last 4 years Dr. Samuels has treated a large number of  RA patients at NYU Hospital for Joint Diseases, and participated in a number of clinical trials involving RA patients.  Dr. Samuels also teaches medical students, residents and fellows throughout the year, and have given lectures on extra-articular manifestations and comorbidities of RA.  He uses musculoskeletal ultrasound in his practice for diagnostic help and procedure (joint injection/aspiration) guidance, and teaches this technique to rheumatologists at conferences throughout the country.

He has authored >20 publications, and serves a variety of leadership functions for clinical rheumatology.  Dr. Samuels received his medical degree from Cornell University Medical College in 1999.

Roy Fleischmann, MD, MACR

Roy Fleischmann, MD, MACR
Co-Medical Director Metroplex Clinical Research Center
Clinical Professor of Medicine
University of Texas Southwestern Medical Center
Dallas, TX

Roy Fleischmann is Clinical Professor of Medicine at the University of Texas Southwestern Medical Center and Medical Director of the Metroplex Clinical Research Center in Dallas, Texas, USA. He received his MD from the State University of New York, Downstate Medical Center, and completed his residency in medicine at Mount Sinai Medical Center in New York City. His fellowship in rheumatology was completed at the College of Physicians and Surgeons of Columbia University, New York. He was elected a Master of the American College of Rheumatology (ACR) in 2010.
Professor Fleischmann has authored over 225 manuscripts and more than 400 abstracts, focusing on the management of rheumatoid arthritis, which have been published in leading international peer-reviewed journals, and presented at prestigious rheumatology meetings worldwide. With more than 35 years of experience as a clinical investigator, Professor Fleischmann has been a principal or co-principal investigator in over 1,000 clinical studies in the field of rheumatology. He has presented frequently at the ACR and EULAR Annual Meetings and  is Editor of Rheumatology and Therapy and on the Editorial Board of the Annals of Rheumatic Disease, RMDOPen and Expert Opinion on Drug Safety. He has served as a reviewer for many peer-reviewed journals including Arthritis & Rheumatism, Annals of Rheumatic Disease, Lancet, the New England Journal of Medicine and the Journal of Rheumatology.
1. Evaluate the role of IL-6 inhibiting therapies in patients with RA for whom methotrexate and anti-TNF medications have failed.
2. Describe how the benefits of anti IL-6/IL-6R therapies may facilitate shared decision-making with patients and improve adherence.
3. Address potential concerns about the anti IL-6/IL-6R safety profile to overcome patient barriers to treatment.

Joint Accreditation Statement 
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and DKBmed, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 
Target Audience
This activity is intended for rheumatologists, PAs, NPs and nurses in rheumatology practices, and some internal medicine clinicians.
Educational Support 
This activity is supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. The faculty reported no financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The following DKB planners and managers Stan Pogroszewski, and Lisa Alvarado hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Jointly provided by Postgraduate Institute for Medicine and DKBmed, LLC.
Estimated time to complete activity: 1.0 hours
Method of Participating and Request for Credit
There are no fees for participation in this CME activity. To receive credit, participants must 1) read the learning objectives and disclosure statements, 2) complete the educational activity and 3) complete the post-test and activity evaluation.
Presented by PIM in collaboration with DKBmed
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.